uniQure (NASDAQ:QURE) Stock Position Lessened by DnB Asset Management AS

DnB Asset Management AS reduced its stake in shares of uniQure (NASDAQ:QURE) by 20.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,028 shares of the biotechnology company’s stock after selling 5,625 shares during the quarter. DnB Asset Management AS’s holdings in uniQure were worth $389,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of QURE. Point72 Asset Management L.P. increased its stake in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares during the period. Walleye Capital LLC acquired a new position in shares of uniQure during the third quarter valued at approximately $444,000. FMR LLC raised its holdings in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC raised its holdings in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in uniQure in the third quarter worth approximately $7,360,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on QURE shares. Stifel Nicolaus boosted their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, March 4th. Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Chardan Capital initiated coverage on shares of uniQure in a research report on Tuesday. They issued a “buy” rating and a $38.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.80.

uniQure Stock Performance

QURE stock opened at $10.62 on Thursday. The stock has a market cap of $574.30 million, a P/E ratio of -2.14 and a beta of 0.37. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a 50 day simple moving average of $13.50 and a 200 day simple moving average of $10.89. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

Insider Transactions at uniQure

In other uniQure news, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by insiders.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.